Following Cobra Biologics’ acquisition of Recipharm AB’s biologics business in June, the business has been re-launched and re-branded under the name of Cobra Biologics. Cobra Biologics has two GMP approved facilities in Södertälje, Sweden (south of Stockholm) and Keele, UK, just south of Manchester.

Julian Hanak, commercial director of Cobra Biologics, said, “From both sites, our organization offers a broad range of integrated and stand-alone development services, stretching from cell line development through to the supply of investigational medicinal product, including regulatory support. We take pride in manufacturing excellence, delivering what we promise and helping our customers to develop drugs for the benefit of patients.”

Peter Coleman, chief executive officer of Cobra Biologics said, “As a newly independent organization, we are delighted to be rebranding with a name that resonates very strongly with the biopharmaceutical sector and which plays to our long established heritage and recognized expertise.”